DE60206174D1 - Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 - Google Patents

Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48

Info

Publication number
DE60206174D1
DE60206174D1 DE60206174T DE60206174T DE60206174D1 DE 60206174 D1 DE60206174 D1 DE 60206174D1 DE 60206174 T DE60206174 T DE 60206174T DE 60206174 T DE60206174 T DE 60206174T DE 60206174 D1 DE60206174 D1 DE 60206174D1
Authority
DE
Germany
Prior art keywords
tyrosine phosphatase
asp
protein tyrosine
cell protein
potas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60206174T
Other languages
English (en)
Other versions
DE60206174T2 (de
Inventor
Kruse Hansen
Hvilsted Olsen
Klarskov Petersen
Jesper Lau
Sune Andersen
Peter Moller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE60206174D1 publication Critical patent/DE60206174D1/de
Publication of DE60206174T2 publication Critical patent/DE60206174T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60206174T 2001-06-29 2002-06-25 Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 Expired - Fee Related DE60206174T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101022 2001-06-29
DK200101022 2001-06-29
DK200200105 2002-01-21
DKPA200200105 2002-01-21
PCT/DK2002/000425 WO2003002569A1 (en) 2001-06-29 2002-06-25 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48

Publications (2)

Publication Number Publication Date
DE60206174D1 true DE60206174D1 (de) 2005-10-20
DE60206174T2 DE60206174T2 (de) 2006-06-22

Family

ID=26069043

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60206174T Expired - Fee Related DE60206174T2 (de) 2001-06-29 2002-06-25 Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48

Country Status (5)

Country Link
EP (1) EP1404682B1 (de)
JP (1) JP2004535451A (de)
AT (1) ATE304545T1 (de)
DE (1) DE60206174T2 (de)
WO (1) WO2003002569A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249865A1 (en) * 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
DK2900674T3 (en) 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2974395C (en) 2015-02-06 2023-08-22 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
EP3551176A4 (de) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetische heterocyclische verbindungen
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
HUP0102612A2 (hu) * 1998-03-12 2001-11-28 Novo Nordisk A/S Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények

Also Published As

Publication number Publication date
ATE304545T1 (de) 2005-09-15
JP2004535451A (ja) 2004-11-25
WO2003002569A1 (en) 2003-01-09
DE60206174T2 (de) 2006-06-22
EP1404682B1 (de) 2005-09-14
EP1404682A1 (de) 2004-04-07

Similar Documents

Publication Publication Date Title
DE60206174D1 (de) Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
ATE449186T1 (de) Zusammensetzungen und verfahren zur selektiven nukleinsäureisolierung
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
ATE359773T1 (de) Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
DE60327811D1 (de) Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
DK0927161T3 (da) Substitueret cyklisk amin-metalloproteaseinhibitorer
DE59508691D1 (de) Verfahren zur sulfonylierung, sulfenylierung und phosphorylierung von cyclischen depsipeptiden
ATE304350T1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DE60219655D1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
PT1163208E (pt) Inibidores de caspase e as suas utilizacoes
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
SE9602263D0 (sv) New amino acid derivatives
ATE383160T1 (de) Phosphinsäurederivate, inhibitoren von beta- sekretase zur behandlung von alzheimer-krankheit
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
EP1298205A4 (de) Neuartige lipase
BR9916255A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos
ATE533495T1 (de) Zusammensetzungen zur behandlung von hautkrankheiten gekennzeichnet durch exsudation von serumproteinen
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
DE60237521D1 (de) Verfahren zur hemmung der ethylenreaktionen von pflanzen
HUP0202613A2 (hu) Növények megváltoztatott aminosav-tartalommal és eljárás előállításukra
DE60329326D1 (de) Tace inhibitoren
HUP0102243A2 (hu) sPLA2-inhibitor vegyületek betegség kezelésére

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee